¡¡¡¡ÔÚ»ñµÃSchering by BayerAG(Leverkusen, Germany)¹«Ë¾µÄÈÏ¿ÉÖ®ºó£¬SiemensͬÒâÒÔ42ÒÚÅ·Ôª¹ºµÃBayerÒ½ÁƱ£½¡¹«Ë¾µÄÕï¶Ïѧ·Ö²¿¡£²¢¹ºÒѾµÃµ½ÁËBayer¼àÊ»áµÄÅú×¼£¬¸Ã·½°¸º¸ÇÁ˶ÔÐí¶à¼²²¡½øÐÐÆÀ¹ÀºÍ¼à²âµÄÌåÍâÕï¶Ï²úÆ·£¬ÊÇÒ»ÏîÅÓ´óµÄͶ×Ê×éºÏ¡£Í¬ÑùÔڸ÷½°¸ÖУ¬°üÀ¨ÁËÓ²¼þ¡¢ÐÅÏ¢¼¼Êõ(IT)ÍøÂç¡¢ºÍ¸´ÔÓÉ豸·þÎñ¡£Bayer¹«Ë¾ÌÇÄò²¡Õï¶Ï²¿ºÍScheringµÄÕï¶ÏÓ°Ïñ²¿Ôò²»°üÀ¨ÔÚÄÚ¡£
¡¡¡¡Siemens Stages Entry as New Diagnostics Powerhouse
¡¡¡¡In a bold push to expand the position of its Medical Solutions group in the fast-growing in vitro and molecular diagnostics markets, Siemens AG has agreed to acquire two major diagnostic companies.
¡¡¡¡Following hard on the news of the acquisition of Schering by BayerAG (Leverkusen, Germany), Siemens agreed to acquire the Diagnostics Division of Bayer HealthCare for €4.2 billion. Included in the acquisition, which has been approved by the Bayer supervisory board, is an extensive portfolio of in vitro diagnostics products for evaluating and monitoring the therapy of numerous diseases. Also included is the systems business, which includes hardware, information technology (IT) networking, and comprehensive equipment service. Not included are the Diabetes Care Division of Bayer and the diagnostic imaging business of Schering.